<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05052437</url>
  </required_header>
  <id_info>
    <org_study_id>BG01-2001</org_study_id>
    <nct_id>NCT05052437</nct_id>
  </id_info>
  <brief_title>PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer</brief_title>
  <official_title>Open, Multicenter, Phase Ic Clinical Study on the Pharmacokinetics and Drug Interactions of Utidelone Plus Capecitabine in Patients With Recurrent and Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Biostar Technologies, Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chengdu Biostar Pharmaceuticals, Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Biostar Technologies, Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is an open, multi-center, phase Ic clinical study on the pharmacokinetics and drug&#xD;
      interactions of utidelone injection combined with capecitabine in patients with recurrent and&#xD;
      metastatic breast cancer.&#xD;
&#xD;
      The purpose of this trial is:&#xD;
&#xD;
        1. To evaluate the pharmacokinetic characteristics of continuous intravenous administration&#xD;
           of utidelone.&#xD;
&#xD;
        2. To evaluate the drug interaction of utidelone and capecitabine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To measure the maximal plasma concentration of the study drugs and evaluate the pharmacokinetic characteristics of continuous intravenous administration of utidelone, measure PK parameters such as Maximum Plasma Concentration [Cmax]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C-T curve</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate the pharmacokinetic interaction of utidelone and capecitabine in patients when administered in combination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To get area under the plasma concentration versus time curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure and plot r-t curve</measure>
    <time_frame>12 weeks</time_frame>
    <description>To analyse mass balance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate the safety of the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Advanced and Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Utidelone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Utidelone plus capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Utidelone Injection; capecitabine</intervention_name>
    <description>8 patients will be assigned to utidelone plus capecitabine arm receiving utidelone plus capecitabine. Utidelone injection 30mg/m2/day, intravenously administered once a day for 5 consecutive days; capecitabine tablets, 1000mg/m2, orally, 2 times a day for 14 consecutive days. 21 days is a cycle</description>
    <arm_group_label>Utidelone plus capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Utidelone</intervention_name>
    <description>8 patients will be assigned to utidelone arm and receive utidelone injection 30 mg/m2/day intravenously, once a day for 5 consecutive days in a 21-day cycle.</description>
    <arm_group_label>Utidelone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily sign an informed consent form, have good compliance, and cooperate with&#xD;
             relevant inspections.&#xD;
&#xD;
          2. Histologically and/or cytologically diagnosed patients with advanced, metastatic&#xD;
             breast cancer.&#xD;
&#xD;
          3. Patients who have previously received at least one anthracycline and taxane drug&#xD;
             therapy (neoadjuvant therapy, adjuvant therapy, or recurrence and metastasis therapy),&#xD;
             or the investigator believes that they can be included in this study.&#xD;
&#xD;
          4. Age ≥18 years; physical condition score ECOG 0~2 points.&#xD;
&#xD;
          5. Within 4 weeks before enrollment, Neuropathy should be less than grade 2 (NCI CTCAE&#xD;
             5.0).&#xD;
&#xD;
          6. Within 1 week before enrollment, routine blood examinations were basically normal&#xD;
             (based on the normal value of each research center laboratory):&#xD;
&#xD;
               1. White blood cell count (WBC) ≥3.0×109/L;&#xD;
&#xD;
               2. Neutrophil count (ANC) ≥ 1.5×109/L;&#xD;
&#xD;
               3. Platelet count (PLT) ≥100×109/L.&#xD;
&#xD;
               4. Hemoglobin ≥9g/dL.&#xD;
&#xD;
          7. Within 1 week before enrollment, liver and kidney function tests were basically normal&#xD;
             (the normal value of each research center laboratory is standard):&#xD;
&#xD;
               1. Total bilirubin (TBIL)≤1.5×upper limit of normal (ULN);&#xD;
&#xD;
               2. Alanine aminotransferase (SGPT/ALT)≤2.5×ULN (for liver metastases≤5×ULN);&#xD;
&#xD;
               3. Aspartate aminotransferase (SGOT/AST)≤2.5×ULN (for liver metastases≤5×ULN);&#xD;
&#xD;
               4. Creatinine clearance rate (Ccr) ≥60 ml/min.&#xD;
&#xD;
          8. No major organ dysfunction.&#xD;
&#xD;
          9. The patient must agree to provide blood, urine and stool samples for pharmacokinetic&#xD;
             studies, and collect them in strict accordance with the required time points and&#xD;
             intervals.&#xD;
&#xD;
         10. No mental abnormality, able to understand and undertake informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who need to receive non-investigative anti-cancer therapy (such as chemotherapy,&#xD;
             immunotherapy or biological therapy) during the administration period of this trial.&#xD;
&#xD;
          2. People who are severely allergic to castor oil, or who have had serious adverse&#xD;
             reactions to anti-microtubule drugs in the past.&#xD;
&#xD;
          3. Within 4 weeks before receiving treatment, have had any major surgery or suffered&#xD;
             major trauma; or are expected to undergo major surgery during the treatment.&#xD;
&#xD;
          4. Pregnancy (positive pregnancy test), breastfeeding patients, or those who are&#xD;
             unwilling to use contraception during the test;&#xD;
&#xD;
          5. Those with uncontrollable intracranial hypertension syndrome (persistent headache,&#xD;
             short-term blurred vision, and/or diplopia)&#xD;
&#xD;
          6. Combined serious diseases, including severe heart disease, cerebrovascular disease,&#xD;
             uncontrolled diabetes, uncontrolled high blood pressure, severe infection, active&#xD;
             peptic ulcer, etc.&#xD;
&#xD;
          7. Known HIV infection, or untreated active hepatitis B or C;&#xD;
&#xD;
          8. Known to have alcohol or drug addiction, or have a history of uncontrollable mental&#xD;
             illness, lack of legal capacity or limited legal capacity;&#xD;
&#xD;
          9. The investigator believes that it is inappropriate to participate in this trial.&#xD;
&#xD;
         10. Participate in another clinical trial or use other research treatments at the same&#xD;
             time.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quchang Ouyang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>RONGGUO QIU, PhD</last_name>
    <phone>01186-56315388</phone>
    <email>rqiu2001@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quchang Ouyang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guoping Yang, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 30, 2021</study_first_submitted>
  <study_first_submitted_qc>September 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>September 12, 2021</last_update_submitted>
  <last_update_submitted_qc>September 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

